Abstract 851P
Background
Acute myeloid leukemia (AML) is a clonal malignancy of the stem cell precursors of the myeloid lineage associate with uncontrolled proliferation and impaired differentiation of hematopoietic stem cells. Among the different genes found amplified in AML, the oncogene MYC is one of the prognostic factors with an impact of AML. Albeit MYC is a well know factor associated with the uncontrolled proliferation of AML, the mechanism that led to the oncogenesis established by MYC are not well known. Zebrafish has recently emerged as a valid model organism to study cancer development because of its genetic accessibility.
Methods
After the generation of a transgenic zebrafish line expressing the human MYC under the control of the neutrophils-specific promoter lysozyme (lyz:hMYC), we proceeded with FACS analysis of adult whole kidney marrow (WKM) of lyz:hMYC fish. Immunohistochemical analysis (IHC) of whole zebrafish was made to check the infiltration of cells and possible metastasis. May-Grunwald stain was made to check the kidney marrow population. Gene expression profile of WKM was performed to check the expression of genes associated with myc and its patthway. We conducted a Metagenomic analysis on possible variations in the intestinal microbiota associated with the disease causing its progression.
Results
FACS analysis of lyz:hMYC zebrafish revealed the expansion of myeloid cells with a significant reduction of erythroid cells, associated with anemia. The IHC analysis of whole lyz:hMYC zebrafish showed infiltration of myeloid cells into different organs confirming that those cells can proliferate unconditionally and metastasise. May-Grunwald analysis showed a higher number of blast cells unable to differentiate towards mature granulocytes in lyz:hMYC zebrafish than in their wild type siblings. The gene expression profile of WKM demonstrated the overexpression of exogenous MYC and of endogenous myc, suggesting a positive auto-regulation of MYC. Metagenomic analysis revealed that the gut microbes of AML fish were significantly altered with the possibility to be associated the progression of AML.
Conclusions
The model developed here is an excellent tool to further understand the mechanisms involved in MYC-induced AML and the relevance of gut microbiota on this disease.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
University of Murcia.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
842P - Multicenter real-world study of newly diagnosed advanced-stage extranodal natural killer/T cell lymphoma (ENKTL): Proposal for intensive therapy
Presenter: Yu-Ce Wei
Session: Poster session 18
844P - Progression -free survival prediction of multiple myeloma patients in five European countries using machine learning models
Presenter: Maria Luisa Pleguezuelo Witte
Session: Poster session 18
845P - A machine learning based clinical platform for cancer subtyping and data integration in hematological malignancies
Presenter: Michelle Tang
Session: Poster session 18
846P - Artificial intelligence-driven identification of onco-hematology patients who may develop severe COVID-19
Presenter: Souad Assaad
Session: Poster session 18
847P - Fatal infections among leukemia patients
Presenter: Huijie Zhou
Session: Poster session 18
848P - Mortality after rasburicase vs allopurinol anti-hyperuricemia monotherapy in patients with liquid tumors
Presenter: Mitchell Cairo
Session: Poster session 18
849P - Long non-coding RNA signatures and their role in the progression of childhood T cell acute lymphoblastic leukemia
Presenter: Pankaj Sharma
Session: Poster session 18
850P - A zebrafish model of MYC-driven acute myeloid leukemia reveals that neutrophil resistance to oncogenic transformation depends on their ability to promote PP2A-mediated MYC proteasomal degradation
Presenter: Anna Maria Luciano
Session: Poster session 18
852P - c-MAF-driven metabolic reprogramming mediates H3K27 hyperacetylation to regulate super enhancer-associated genes
Presenter: Phyllis SY Chong
Session: Poster session 18
946P - Sintilimab plus lenvatinib as conversion therapy in patients with unresectable hepatocellular carcinoma: A prospective, non-randomized, open-label, phase II, expansion cohort study
Presenter: Shichun Lu
Session: Poster session 18